Amazon’s PillPack may be cut off from accessing patient data. Amazon has threatened to sue electronic-prescribing company Surescripts, which is owned by PillPack competitors CVS and Express Scripts, for attempting to end PillPack’s access to patient data. (CNBC)

Viiv’s chief scientific and medical officer is stepping down after a decade. John Pottage’s dual role will be split after his departure in October. Kim Smith, head of global research and medical strategy, will take over the role of chief scientific officer, while  Har­mo­ny Garges, head of glob­al med­ical af­fairs, will be­come medical chief. (Endpoints)

Amgen and Allergan have launched the first U.S. biosimilars of Roche cancer drugs. The biosimilars are copies of chemotherapy treatments Herceptin and Avastin. A judge blocked Roche’s request for an injunction to prevent biosimilars from reaching the market this week. (BioPharma Dive)

Analysts have predicted that Celgene psoriasis drug Otezla will likely be bought by Gilead, Amgen or Johnson & Johnson. The analysts also expect Otezla to sell for $5 billion to $10 billion. Celgene is required to sell the drug to complete its acquisition by Bristol-Myers Squibb. (BioPharma Dive)

Canada will continue importing Kaleo’s epinephrine shot. Canada, along with the U.S. and Europe, has been experiencing shortages of the branded EpiPen. Pfizer, which manufactures Mylan’s EpiPen in North America, expects the shortage to be resolved in October. (Reuters)